Naveen Gupta joins LambdaTest as its Chief Financial Officer
6.4.2023 15:30:00 EEST | Business Wire | Press release
LambdaTest, an intelligent omnichannel digital experience testing cloud platform, has announced the appointment of Naveen Gupta as its Chief Financial Officer. He comes with more than 35 years of experience across industries and brings a wealth of financial and strategic experience to LambdaTest, having held several executive roles at prominent companies in the past.
In his new role at LambdaTest, Naveen will lead the finance and accounting functions, helping to drive the company's growth and profitability. He will be responsible for financial planning, revenue projections, profit, business growth objectives, and risk management, among other responsibilities.
Naveen was most recently the CFO at Innovaccer, a Silicon Valley-based digital healthcare company. He was previously with Thomson Reuters, Pangea3 (acquired by Thomson Reuters), GlobalLogic India, and Xansa among other companies.
“Naveen comes with deep strategic expertise in scaling finance functions at technology companies and would be an invaluable asset for us. His three-and-a-half decades track record speaks for itself. Naveen will be our guiding light when it comes to growth and profitability. We are excited to welcome him to the LambdaTest rocketship,” said Asad Khan, CEO, LambdaTest.
“The innovation that LambdaTest is doing to disrupt the digital experience testing landscape excited me. The potential that such core innovation has is immense. Additionally, LambdaTest’s deep focus on partnerships to enable an integrated enterprise execution environment will fundamentally change the siloed approach to testing and will give companies a unified and streamlined experience,” said Naveen Gupta, CFO, LambdaTest. “The company leadership’s vision on productivity and efficiency is deep-rooted and my task is to carry forward the baton and strategically move towards growth and profitability. I’m looking forward to this journey.”
LambdaTest also recently announced the launch of its digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options–public cloud, single tenant, or on-premise.
About LambdaTest
LambdaTest is an intelligent unified digital experience testing cloud that helps businesses drastically reduce time to market through faster test execution, ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
Continuous Testing Cloud
LambdaTest's Continuous Testing Cloud allows enterprises to rapidly test and deploy changes to their web and mobile applications up to 70% faster, which helps to accelerate the development process and improve time-to-market.
Cross-browser Testing Cloud
Our cross-browser testing cloud allows users to test their websites and web applications on a wide variety of browsers, operating systems, and devices. With features such as real-time testing, responsive design testing, and debugging tools, it enables developers to ensure that their websites and web apps are compatible with different browsers, thereby providing a seamless user experience.
Real Device Cloud
With real device cloud, testers/developers can catch bugs early before their mobile apps go live. With LambdaTest's Real Devices Testing Cloud, teams can test unhandled errors, UI/UX, performance, and functionality of their apps before they get released into production. The teams can also test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV).
AI-powered Visual Regression Cloud
Ensuring consistent layouts, designs, and functionality of applications is crucial to deliver visually-perfect digital experiences. LambdaTest's visual regression cloud ensures that the visual appearance and functionality of an organization’s web applications remain consistent and error-free, ultimately improving the digital experience and business performance. Teams can get early insights on visual UI bugs before they release their applications to the customer. Testers/developers can run automated visual regression tests on 3000+ combinations of browsers & real devices to identify visual deviations.
AI-powered Integrated Test Intelligence
Test execution insights are critical for digital transformation as they provide enterprises with deeper insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's integrated test intelligence provides enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality. This can empower development teams with detailed and actionable test execution data and close the gap between data, insight, and action for better and faster decision-making.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005372/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom